Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "KEYNOTE"

71 News Found

AIIMS, New organises conference on ‘Advancing Oral Health in India’
Healthcare | October 06, 2024

AIIMS, New organises conference on ‘Advancing Oral Health in India’

Poor oral health (periodontal disease) impacts nearly 51% of Indians


Decline in TB incidence by 16% from 237 per hundred thousand population in 2015 to 199 in 2022
News | September 25, 2024

Decline in TB incidence by 16% from 237 per hundred thousand population in 2015 to 199 in 2022

She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all


Sightsavers India and AbbVie India host consultation on Glaucoma prevention in Bhopal
Healthcare | September 23, 2024

Sightsavers India and AbbVie India host consultation on Glaucoma prevention in Bhopal

The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up


Astec Lifesciences appoints Prof. G. D. Yadav as Independent Director
People | September 18, 2024

Astec Lifesciences appoints Prof. G. D. Yadav as Independent Director

Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India


10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma
Diagnostic Center | September 16, 2024

10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab


Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC
Diagnostic Center | September 16, 2024

Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC

KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival


National conference on `Universal Access to Health care: Digital Solutions’ at IHC
Digitisation | September 06, 2024

National conference on `Universal Access to Health care: Digital Solutions’ at IHC

The conference aims to bring various stakeholders and experts in the field of healthcare and digital solutions for ensuring ‘universal access to affordable and quality healthcare’


Health Ministry launches 2nd phase of Mass Drug Administration Campaign 2024 to eliminate Lymphatic Filariasis
Policy | August 11, 2024

Health Ministry launches 2nd phase of Mass Drug Administration Campaign 2024 to eliminate Lymphatic Filariasis

The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh


Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda
Diagnostic Center | June 05, 2024

Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda

The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer


FDA grants priority review to Merck’s application for Keytruda plus chemotherapy for metastatic malignant pleural mesothelioma
Drug Approval | May 30, 2024

FDA grants priority review to Merck’s application for Keytruda plus chemotherapy for metastatic malignant pleural mesothelioma

Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients